Increased expression and plasma levels of myeloperoxidase are closely related to the presence of angiographically-detected complex lesion morphology in unstable angina


Published in:
Heart

DOI:
10.1136/hrt.2009.187609

Citation for published version (APA):
Naruko, T., Furukawa, A., Yunoki, K., Komatsu, R., Nakagawa, M., Matsumura, Y., ... Ueda, M. (2010). Increased expression and plasma levels of myeloperoxidase are closely related to the presence of angiographically-detected complex lesion morphology in unstable angina. Heart, 96(21), 1716-1722. DOI: 10.1136/hrt.2009.187609
Increased expression and plasma levels of myeloperoxidase are closely related to the presence of angiographically-detected complex lesion morphology in unstable angina

T Naruko,1 A Furukawa,1 K Yunoki,1 R Komatsu,1 M Nakagawa,2 Y Matsumura,3 N Shirai,3 K Sugioka,3 M Takagi,3 T Hozumi,3 A Itoh,1 K Haze,1 M Yoshiyama,3 A E Becker,4 M Ueda2

ABSTRACT

Background Myeloperoxidase (MPO) is a leucocyte enzyme that catalyses the formation of a number of reactive oxidant species.

Objective The purpose of this study is to evaluate the relationship between angiographic coronary plaque morphology in patients with unstable angina pectoris (UAP) or stable angina pectoris (SAP) and MPO levels.

Patients and design Plasma MPO levels on admission were measured in 236 patients with UAP, 146 with SAP and 85 control subjects using an ELISA kit. The angiographic morphology of the culprit lesion was classified into two types, simple or complex, based on the Ambrose classification. In addition, 61 atherectomy specimens obtained from a different cohort of patients with UAP and SAP were studied immunohistochemically for MPO.

Results Median (IQR) plasma MPO levels in patients with UAP with a complex lesion were significantly higher than in patients with a simple lesion (41.9 (21.7–73.7) ng/ml vs 20.5 (15.9–27.9) ng/ml, p<0.0001), but there was no significant difference between the two groups in patients with SAP. On multivariate analysis, raised plasma MPO levels and Braunwald class III were independent factors associated with SAP. On multivariate analysis, raised plasma MPO levels and Braunwald class III were independent factors associated with SAP. On multivariate analysis, raised plasma MPO levels and Braunwald class III were independent factors associated with SAP.

Conclusions This study shows that increased expression and plasma MPO levels are closely related to the presence of angiographically-detected complex lesion morphology in patients with UAP.

Coronary vascular inflammation plays a pivotal role in most cases of acute coronary syndromes. As previously demonstrated by us and others, macrophages, T lymphocytes and neutrophils are the dominant types of inflammatory cells in human coronary unstable, eroded or ruptured plaques.1 2 Unstable angina pectoris (UAP) is a clinical heterogeneous condition in which the severity of symptoms and the risk of progression to infarction or of sudden death vary widely between reported clinical series.3 4 Previous clinical studies have reported that angiographic findings of culprit lesions in patients with UAP frequently appear to be irregular and contain filling defects likely to represent plaque disruption and/or thrombus.5–8 Pathological studies showed that these angiographic appearances were caused by plaque disruption in which a mass of thrombus projected into the lumen but antegrade flow still remained.9 Moreover, in a previous immunohistochemical study, atherectomy specimens from patients with UAP with angiographic complex lesions had a greater percentage of macrophages than those from patients with angiographic simple lesions.10

Myeloperoxidase (MPO) is an abundant haemoprotein released mainly by activated neutrophils and present in some tissue macrophages such as those in vascular lesions.11–13 MPO has been linked to the development of lipid-rich soft plaque,14 the activation of protease cascades affecting the stability and thrombogenicity of plaque.15 Moreover, MPO levels have been shown to predict the risk of clinical events in subjects presenting with chest pain or acute coronary syndromes.16–23

In the present study we measured plasma MPO levels in patients with UAP and those with stable angina pectoris (SAP) and investigated whether there is a relationship between plasma MPO levels and angiographic coronary lesion morphology. Additionally, in a second group of patients with UAP and SAP we examined immunohistochemically the presence of MPO-positive cells using specimens obtained by directional coronary atherectomy (DCA) and evaluated the association between the angiographic plaque morphology of the culprit lesion and the infiltration of MPO-positive cells in these atherectomy specimens. We also investigated the association between the number of MPO-positive cells in atherectomy specimens and plasma MPO levels.

METHODS

The present study comprised two distinct groups: group I consisted of 382 patients from whom plasma MPO levels were obtained and group II consisted of 61 different patients from whom atherectomy specimens were obtained. In the group II cohort we were able to obtain plasma MPO levels from 28 patients with UAP.
Group I (plasma MPO)
Patients
This cohort consisted of 256 consecutive patients with UAP who underwent coronary angiography within 3 days of hospital admission and had angiographically documented narrowing of at least 70% of the luminal diameter of a major coronary artery between April 2006 and December 2008. Patients with variant angina, concomitant inflammatory diseases, renal failure or neoplastic diseases were not entered in the study. The patients with SAP were further divided into class I (n=84), class II (n=22) and class III (n=130) according to Braunwald’s criteria. All patients had primary SAP, as defined by subclass ‘B’ of the Braunwald classification. After being admitted, all patients received aspirin, with 75% of the patients receiving antianginal treatment (β blockers, nitrates or calcium-channel alone or in combination). High-risk patients were also treated with intravenous heparin or intravenous nitroglycerin. Before admission, lipid-lowering agents were administrated to 55 patients but none used antioxidant drugs. In addition, plasma MPO levels were measured in 146 patients with SAP and in 85 normal subjects. SAF was defined as chest pain typical of cardiac ischaemia on exertion. All patients with SAP had undergone coronary angiography and had angiographically documented narrowing of at least 70% of the luminal diameter of a major coronary artery. Normal subjects comprised 85 age- and gender-matched healthy volunteer blood donors (55 men and 32 women; mean±SD age 63±9 years). The following measurements were performed: serum levels of total cholesterol, high density lipoprotein (HDL) cholesterol and LDL cholesterol, triglycerides, serum high sensitivity C-reactive protein (hs-CRP) levels, leucocyte count, neutrophil count and plasma MPO levels.

Biochemical analysis
Venous blood samples from all patients were obtained on admission to the hospital, prior to heparin administration. Serum hs-CRP levels were assayed with the use of latex-enhanced immunonephelometric assays on a BN II analyser (Dade Behring, Newark, Delaware, USA). Plasma MPO levels were measured with an ELISA method (Oxis) according to procedures previously reported.

Group II (MPO expression in atherectomy specimens and plasma MPO)
Patients
Coronary atherectomy specimens were obtained by DCA performed between December 2005 and December 2007 from the culprit lesions in 61 patients who presented with either SAP (n=28) or UAP (n=33). Fifteen of the patients have been reported in another study. The patients with UAP consisted of 13 patients in Braunwald class I, 2 in class II and 18 in class III. The culprit lesion was identified using clinical, ECG and angiographic data. The time interval between diagnostic coronary angiography and DCA ranged from 0 to 3 days. Immediately after DCA, the tissue specimens were carefully orientated along their longest axis, snap frozen, stored at −80°C and then serially sectioned at 6 μm thickness and fixed in acetone. Every first section was stained with haematoxylin-eosin and the other sections were used for immunohistochemical staining. In addition, venous blood samples from 28 of the 33 patients with UAP were obtained prior to heparin administration, and plasma MPO levels and serum hs-CRP levels in these 28 patients were also measured according to procedures previously reported.

Immunohistochemistry
The cellular components were analysed using monoclonal antibodies against smooth muscle cell (SMC) actin (1A4, DAKO, Glostrup, Denmark), macrophages (EBM11, DAKO), neutrophils (CD66b, Beckman Coulter, Fullerton, California, USA) and MPO (MPO-7, DAKO). In addition, platelets were detected with a monoclonal antibody against GPIIb/IIIa (CD41, DAKO). Non-immune mouse IgG serum (DAKO) served as a negative control. Sections were incubated at 4°C overnight or 1 h at room temperature and then subjected to a three-step staining procedure using the streptavidin-biotin complex method (SABC) for detection. Peroxidase activity was visualised with 3-amino-ethyl-carbazole (10 min, room temperature) and the sections were faintly counterstained with haematoxylin. Simultaneous identification of SMCs and macrophages was carried out using two primary antibodies to different IgG subclass proteins (1A4/CD68), as reported previously. To identify cell types that stained positive for MPO, immunodouble staining with neutrophils (CD66b) or macrophages (CD68) and MPO were also performed according to the method previously reported with minor procedural modifications.

Quantitative methods
The tissue area occupied by immunostained macrophages, SMCs and GPIIb/IIIa was quantified using computer-aided planimetry and expressed as a percentage of the total surface area of the tissue sections. The numbers of MPO-positive cells and CD66b-positive neutrophils were counted in the entire tissue sections and expressed as the number of cells per mm² of tissue. MPO-positive cells and CD66b-positive neutrophils within thrombi or tissue-attached blood clots were excluded. Morphometric analysis was performed by a single investigator blinded to the patients’ characteristics and histological classifications.

Coronary angiography analysis
Angiography was performed so that each lesion could be viewed from at least two angles. The coronary lesion was identified as the ‘culprit lesion’ based on clinical and ECG findings. In all patients, offline quantitative coronary angiography (QCA) was conducted with the view revealing the highest degree of stenosis. Pre-intervention angiographic morphology was evaluated by two independent observers who were unaware of the patient’s clinical status or Braunwald classification. In cases of disagreement, consensus was reached by further joint reading. Angiographic morphology was divided into two types as either simple or complex based on the Ambrose classification. In our analysis, total occlusions and intracoronary thrombus were considered complex lesions and were not classified as separate angiographic variables. The interobserver agreement for angiographic morphology was 91% and intraobserver agreement was 92%. Left ventriculography was performed on admission and left ventricular ejection fraction (LVEF) was calculated.

Statistical analyses
Results for normally distributed continuous variables are expressed as mean±SD and continuous variables with non-normal distribution are presented as median (interquartile range). The two groups were compared with an unpaired Student t test or Mann–Whitney U test when the variance was heterogeneous. Statistical comparisons between more than three groups were performed by one-way analysis of variance (ANOVA) and post hoc multiple comparison by the Scheffe test. Levels of MPO and hs-CRP did not distribute normally so logarithmically-transformed values of MPO and hs-CRP were...
used as variables for statistical analyses. Categorical variables were compared with the \( \chi^2 \) test. Multivariate logistic regression analysis was performed to identify independent factors associated with angiographically-detected complex lesions. Pearson correlation coefficients were calculated to assess the relationship between log-transformed MPO or hs-CRP levels and diameter stenosis (DS), minimal lumen diameter (MLD) or the number of MPO-positive cells. Values of \( p < 0.05 \) were considered significant.

**RESULTS**

**Group I**

**Plasma MPO levels and clinical severity**

As shown in figure 1A, plasma MPO levels in patients with class III UAP were significantly higher than in patients with class I UAP (\( p < 0.005 \)), patients with SAP (\( p < 0.0001 \)) or in control subjects (\( p < 0.0001 \)) (class II UAP: \( 39.9 \) (19.7–62.5) ng/ml; class II UAP: \( 25.3 \) (18.6–42.3) ng/ml; class I UAP: \( 21.6 \) (17.0–31.9) ng/ml; SAP: \( 18.7 \) (15.4–24.1) ng/ml; controls: \( 15.6 \) (13.9–18.8) ng/ml). The plasma levels of MPO in patients with SAP and those with class I UAP or class II UAP were also significantly higher than those in control subjects (SAP vs control, \( p < 0.01 \); UAP class I vs control, \( p < 0.0001 \); UAP class II vs control, \( p < 0.001 \)).

**Plasma MPO levels and coronary angiographic morphology**

There was no significant correlation between plasma MPO levels and DS or MLD of the culprit lesion in patients with SAP or UAP (SAP: MPO vs DS, \( p = 0.96 \); MPO vs MLD, \( p = 0.50 \); UAP: MPO vs DS, \( p = 0.59 \); MPO vs MLD, \( p = 0.58 \)). In this group I cohort, 52 of the 146 culprit lesions in patients with SAP and 159 of the 256 culprit lesions in patients with UAP showed angiographic evidence of a complex lesion. Table 1 shows the characteristics of patients with angiographically-detected simple and complex lesions. In patients with UAP with a complex lesion, Braunwald class III was more frequent than in those with a simple lesion (62% vs 45%, \( p = 0.01 \)). In the QCA analysis, pre-procedure MLD and DS in patients with a complex lesion were significantly higher than in those with a simple lesion (SAP: MLD, \( p < 0.0001 \); DS, \( p < 0.001 \); UAP: MLD, \( p = 0.04 \); DS, \( p = 0.02 \)). As shown in figure 1B, plasma MPO levels in patients with UAP with a complex lesion were significantly higher than in those with a simple lesion (41.9 (21.7–75.7) ng/ml vs 20.5 (15.9–27.9) ng/ml; \( p < 0.0001 \)); however, there was no significant difference between those with complex and those with simple lesions in patients with SAP (19.3 (16.3–24.0) ng/ml vs 18.2 (14.8–24.7) ng/ml).

Moreover, as shown in figure 1C, plasma MPO levels in patients with a complex lesion were significantly higher than those in patients with a simple lesion in each of Braunwald class I and class III (class I: simple 20.7 (15.9–26.0) ng/ml, complex 27.6 (18.1–50.4) ng/ml, \( p < 0.05 \); class II: simple 21.5 (17.1–37.1) ng/ml, complex 35.5 (21.7–73.7) ng/ml; \( p = NS \); class III: simple 19.5 (16.1–32.0) ng/ml, complex 47.5 (29.9–81.0) ng/ml, \( p < 0.0001 \)).

To identify independent factors associated with angiographically-detected complex lesions in patients with UAP, a multivariate logistic regression analysis was performed using age, gender, risk factors, Braunwald class III, prevalence of elevated levels of troponin T, HDL cholesterol and LDL cholesterol, pre-procedure MLD, LVEF, neutrophil counts, serum hs-CRP levels and plasma MPO levels. Multivariate analysis showed that plasma MPO levels and Braunwald class III were independent factors associated with angiographically-detected complex lesions (MPO: adjusted OR 12.49, 95% CI 3.24 to 48.17, \( p = 0.0002 \); Braunwald class III: adjusted OR 2.80, 95% CI 1.32 to 5.94, \( p = 0.0075 \)). In addition, multivariate analysis in patients with Braunwald class III showed that the plasma MPO level was only an independent factor associated with angiographically-detected complex lesions (MPO: adjusted OR 11.22, 95% CI 3.18 to 39.56, \( p = 0.0007 \)).

**Group II**

(MPO expression in atherectomy specimens and plasma MPO)

Immunohistochemical quantification in atherectomy specimens

In this group II cohort, 21 of the 33 culprit lesions of patients with UAP and 3 of the 28 culprit lesions of patients with SAP showed angiographic evidence of a complex lesion. Regarding age, male gender and coronary risk factors, there were no statistically significant differences between simple and complex lesions in patients with SAP or UAP. In the 18 patients with UAP...
with Braunwald class III, angiographic complex lesions were observed in 15 patients (83%) and angiographic simple lesions were found in 3 patients (17%) while, in the 15 patients with Braunwald class I and II, angiographic complex lesions were observed in 6 patients (40%). In the culprit lesions of patients with SAP, 12 of the 28 lesions (43%) contained foci of macrophages and only 1 of the 28 lesions (4%) contained neutrophils. In contrast, all 33 lesions in patients with UAP contained MPO-positive cells, p < 0.0005 higher than in Braunwald class III (figure 3A). In patients with UAP the number of CD66-positive neutrophils and MPO-positive cells was significantly higher in complex lesions than in simple lesions (CD66-positive neutrophils, p < 0.0005; MPO-positive cells, p < 0.0005). In addition, the percentage of GP IIIa/IIa-positive area was significantly (p < 0.0005) higher in complex lesions than in simple lesions. However, there was no significant difference in the percentage of macrophage-positive or SMC-positive areas between the two groups (figure 3B). With regard to the relationship between MPO-positive cells and the Braunwald classification, the number of MPO-positive cells in Braunwald class III patients was significantly higher (p < 0.05) than in Braunwald class I and II patients. Moreover, in both groups the number of MPO-positive cells was significantly higher in complex lesions than in simple lesions (Braunwald class I and II: simple 9.4 ± 8.7 mm², complex 32.2 ± 18.2 mm², p < 0.05; Braunwald class III: simple 11.8 ± 5.9 mm², complex 43.9 ± 25.6 mm², p < 0.05, figure 3C). In the group II cohort, plasma MPO levels were positively correlated with the number of MPO-positive cells in atherectomy specimens (R = 0.42, p = 0.024, figure 3D). In contrast, there was no significant correlation between serum hs-CRP levels and the number of MPO-positive cells in these patients with UAP.

**DISCUSSION**

Angiographic complex coronary plaque morphology is the angiographic hallmark of acute coronary syndromes and correlates with pathologic plaque rupture and thrombosis. Maehara et al, using coronary intravascular ultrasound, showed that complex lesions represent atherogenic vulnerable plaques prone to disruption or actually disrupted plaques. To the best of our knowledge, this is the first study to show that increased

---

**Table 1** Clinical and angiographic characteristics of patients with SAP and UAP in whom MPO was quantified between angiographically-detected simple versus complex lesion groups

<table>
<thead>
<tr>
<th></th>
<th>Simple (n = 94)</th>
<th>Complex (n = 52)</th>
<th>p Value</th>
<th>UAP</th>
<th>Simple (n = 97)</th>
<th>Complex (n = 139)</th>
<th>p Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>65 ± 9</td>
<td>65 ± 10</td>
<td>0.95</td>
<td>65 ± 10</td>
<td>66 ± 10</td>
<td>0.30</td>
<td></td>
</tr>
<tr>
<td>Male (%)</td>
<td>77</td>
<td>81</td>
<td>0.56</td>
<td>75</td>
<td>71</td>
<td>0.42</td>
<td></td>
</tr>
<tr>
<td>Hypertension (%)</td>
<td>68</td>
<td>62</td>
<td>0.64</td>
<td>72</td>
<td>66</td>
<td>0.33</td>
<td></td>
</tr>
<tr>
<td>Hypercholesterolaemia (%)</td>
<td>54</td>
<td>50</td>
<td>0.82</td>
<td>51</td>
<td>58</td>
<td>0.29</td>
<td></td>
</tr>
<tr>
<td>Diabetes mellitus (%)</td>
<td>40</td>
<td>37</td>
<td>0.64</td>
<td>32</td>
<td>40</td>
<td>0.23</td>
<td></td>
</tr>
<tr>
<td>Smoking (%)</td>
<td>64</td>
<td>52</td>
<td>0.16</td>
<td>53</td>
<td>50</td>
<td>0.86</td>
<td></td>
</tr>
<tr>
<td>Braunwald class III (%)</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>45</td>
<td>62</td>
<td>0.01</td>
<td></td>
</tr>
<tr>
<td>Total cholesterol (mg/dl)</td>
<td>194 ± 32</td>
<td>—</td>
<td>0.06</td>
<td>201 ± 34</td>
<td>201 ± 40</td>
<td>0.94</td>
<td></td>
</tr>
<tr>
<td>LDL cholesterol (mg/dl)</td>
<td>49 ± 13</td>
<td>45 ± 11</td>
<td>0.06</td>
<td>48 ± 11</td>
<td>48 ± 11</td>
<td>0.10</td>
<td></td>
</tr>
<tr>
<td>Triglycerides (mg/dl)</td>
<td>156 ± 94</td>
<td>178 ± 128</td>
<td>0.24</td>
<td>152 ± 90</td>
<td>143 ± 82</td>
<td>0.46</td>
<td></td>
</tr>
<tr>
<td>Elevated TnT &gt;0.1 ng/ml (%)</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>20</td>
<td>26</td>
<td>0.26</td>
<td></td>
</tr>
<tr>
<td>Medications at hospital admission</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Aspirin (%)</td>
<td>59</td>
<td>67</td>
<td>0.30</td>
<td>100</td>
<td>100</td>
<td>—</td>
<td></td>
</tr>
<tr>
<td>Beta-blockers (%)</td>
<td>16</td>
<td>29</td>
<td>0.06</td>
<td>25</td>
<td>30</td>
<td>0.39</td>
<td></td>
</tr>
<tr>
<td>Calcium antagonists (%)</td>
<td>56</td>
<td>48</td>
<td>0.34</td>
<td>59</td>
<td>53</td>
<td>0.34</td>
<td></td>
</tr>
<tr>
<td>Nitrates (%)</td>
<td>33</td>
<td>40</td>
<td>0.37</td>
<td>31</td>
<td>29</td>
<td>0.77</td>
<td></td>
</tr>
<tr>
<td>ACE inhibitors/ARB (%)</td>
<td>18</td>
<td>31</td>
<td>0.08</td>
<td>48</td>
<td>43</td>
<td>0.37</td>
<td></td>
</tr>
<tr>
<td>Lipid-lowering agents (%)</td>
<td>28</td>
<td>37</td>
<td>0.27</td>
<td>34</td>
<td>35</td>
<td>0.87</td>
<td></td>
</tr>
<tr>
<td>QCA analysis</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Reference diameter (mm)</td>
<td>3.0 (2.6–3.4)</td>
<td>2.7 (2.4–3.1)</td>
<td>0.04</td>
<td>3.2 (2.9–3.5)</td>
<td>3.1 (2.7–3.5)</td>
<td>0.04</td>
<td></td>
</tr>
<tr>
<td>MLD (mm)</td>
<td>0.64 (0.43–0.79)</td>
<td>0.28 (0.02–0.53)</td>
<td>&lt;0.001</td>
<td>0.48 (0.07–0.72)</td>
<td>0.30 (0–0.59)</td>
<td>0.04</td>
<td></td>
</tr>
<tr>
<td>DS (%)</td>
<td>78 (75–86)</td>
<td>91 (83–99)</td>
<td>&lt;0.001</td>
<td>60 (54–65)</td>
<td>88 (81–99)</td>
<td>0.02</td>
<td></td>
</tr>
<tr>
<td>Multiple complex plaque (%)</td>
<td>—</td>
<td>19</td>
<td>—</td>
<td>29</td>
<td>—</td>
<td>—</td>
<td></td>
</tr>
<tr>
<td>LVEF (%)</td>
<td>59 ± 11</td>
<td>58 ± 10</td>
<td>0.84</td>
<td>59 ± 9</td>
<td>57 ± 9</td>
<td>0.13</td>
<td></td>
</tr>
<tr>
<td>Leucocyte count (l/mm³)</td>
<td>(5103–7308)</td>
<td>6315 (5138–7388)</td>
<td>0.77</td>
<td>6600 (5510–7950)</td>
<td>6550 (5543–8175)</td>
<td>0.47</td>
<td></td>
</tr>
<tr>
<td>Neutrophil count (l/mm³)</td>
<td>3472 (2721–4461)</td>
<td>3480 (2775–4448)</td>
<td>0.90</td>
<td>3793 (3090–5112)</td>
<td>4118 (3256–5163)</td>
<td>0.16</td>
<td></td>
</tr>
<tr>
<td>hs-CRP (mg/dl)</td>
<td>0.11 (0.05–0.22)</td>
<td>0.09 (0.05–0.19)</td>
<td>0.55</td>
<td>0.13 (0.06–0.31)</td>
<td>0.14 (0.05–0.34)</td>
<td>0.86</td>
<td></td>
</tr>
<tr>
<td>MPO (ng/ml)</td>
<td>18.2 (14.8–24.7)</td>
<td>19.3 (16.3–24.0)</td>
<td>0.43</td>
<td>20.5 (15.9–27.9)</td>
<td>41.9 (21.7–73.8)</td>
<td>&lt;0.0001</td>
<td></td>
</tr>
</tbody>
</table>

**Categorical variables are expressed as percentages and continuous variables as mean±SD or median (interquartile ranges) as appropriate.**

ACE, angiotensin converting enzyme; ARB, angiotensin II type 1 receptor blockers; DS, diameter stenosis; HDL, high density lipoprotein; hs-CRP, high-sensitivity C-reactive protein; LDL, low density lipoprotein; LVEF, left ventricular ejection fraction; MLD, minimal lumen diameter; MPO, myeloperoxidase; QCA, quantitative coronary angiography; SAP, stable angina pectoris; TnT, troponin T; UAP, unstable angina pectoris.
Figure 2  (A) Angiographic image showing a complex lesion (arrow). (B–F) Micrographs of an atherectomy specimen obtained from a complex culprit lesion. (B) Double immunostaining for SMC (turquoise) and macrophage (red). (C) Immunostaining for platelets (GP IIb/IIIa). (D) Immunostaining for neutrophils (CD66b). (E) Immunostaining for MPO (MPO-7). (F) Double immunostaining for MPO-7 (blue) and CD66b (red) shows that most cells show double staining (purple), indicating that most MPO-7-positive cells are neutrophils. Bar: 100 mm (B–F). (G) Angiographic image showing a simple lesion (arrow). (H–J) Micrographs of an atherectomy specimen obtained from a simple culprit lesion. (H) Double immunostaining for SMC (turquoise) and macrophage (red). (I) Immunostaining for CD66b. (J) Immunostaining for MPO. Bar: 100 mm (H–J). MPO, myeloperoxidase; SMC, smooth muscle cell.
plasma levels of MPO are related to the presence of angiographically-detected complex lesion morphology. In addition, we have demonstrated the relationship between angiographic coronary lesion morphology and the magnitude of MPO-positive cell infiltration in patients with UAP using coronary angiography. Recent studies reported that there were no significant differences between the low-MPO group and the high-MPO group with regard to DS or MLD of the culprit lesion in patients with SAP or UAP. Several studies have shown the relationship between biomarkers and plaque instability. Inokubo et al. demonstrated that the release of MMP-9 or TIMP-1 from unstable or ruptured plaques and from circulating neutrophils is a biomarker in the management and risk stratification of these patients.

**Limitations**

This study lacked a contemporary assessment of plaque morphology by ultrasound or optical coherence tomography. Serrano et al. have shown that the angiographic characteristics of the culprit lesion correlate poorly with the intensity of the inflammatory response induced by coronary stent implantation in patients with SAP. However, in patients with UAP, several studies have reported that angiographically complex lesions are strongly associated with disrupted plaques and/or thrombus formation as assessed by ultrasound and by angioscopy. This is an important observation and lends support to our use of angiographic assessment of plaque complexity. Future studies...
should confirm an association between plasma MPO levels and plaque morphology as assessed by ultrasound or optical coherence tomography.

CONCLUSIONS

This study shows that increased expression and plasma levels of MPO are closely related to the presence of angiographically-detected complex lesion morphology and can be considered an important biomarker in the management and risk stratification of patients with UAP.

Competing interests None.

Patient consent Obtained.

Ethics approval This study was conducted with the approval of the Osaka City General Hospital ethics committee.

Provenance and peer review Not commissioned; externally peer reviewed.

REFERENCES

1. van der Wal AC, Becker AE, van der Loos CM, et al. Site of intimal rupture or erosion of thrombosed coronary atherosclerotic plaques is characterized by an inflammatory process irrespective of the dominant plaque morphology. Circulation 1994;89:36–44.
with medical treatment alone therefore seems the most appropriate management of patients with SCAD who become asymptomatic with medical treatment and who do not show any evidence of ongoing ischaemia or haemodynamic instability. Revascularisation seems only warranted in cases of recurrent anginal symptoms and should be considered when, after prolonged medical treatment, a pronounced dissection persists in a major coronary artery causing a marked and extensive inducible myocardial ischaemia upon myocardial perfusion imaging.

Christian J M Vrints
Correspondence to Christian J M Vrints, University of Antwerp,University Hospital, Wijnikstraat 10, Edegem 2650, Belgium; christian.vrints@ua.ac.be
Competing interests None.
Provenance and peer review Commissioned; not externally peer reviewed.

Published Online First 5 October 2010
Heart 2010;96:2043–2044. doi:10.1136/hrt.2010.205997

REFERENCES

Short-term effects of transcatheter aortic valve implantation

To the Editor I read with interest the paper by Gotzmann et al in Heart1 demonstrating some very important differences after transcatheter aortic valve implantation (TAVI), particularly improvements in exercise tolerance and quality of life. I do have some reservations, however, on the statistical methodology employed. The study involved a cohort of 44 patients, assessed before and after TAVI, so clearly paired statistical tests are appropriate. However, the group chose to use the unpaired Student t, Mann–Whitney U and χ² tests, instead of the correct (and more powerful) paired Student t, Wilcoxon and McNemar tests. Use of these tests would very probably have considerably increased the significance of observed differences.

On the other hand, the paper contains at least 16 independent comparative tests, and no allowance has been made for multiple comparison. Using the crudest method of correction (the Bonferroni correction), they should have considered tests to be significant not at p<0.05, but at p<0.003, which would render some of the apparent significant differences to be not significant (such as LVEF and BNP).

I would recommend that the authors re-examine their stats before making the conclusions about BNP stated in the paper; it may turn out that (using the Wilcoxon test) BNP is in fact significantly reduced after TAVI in this group of patients.

David Cunningham
Correspondence to David Cunningham, Director, Central Cardiac Audit Database (CCAD), UK; david.cunningham@ccad.ni.nhs.uk
Competing interests None declared.

Provenance and peer review Not commissioned; not externally peer reviewed.

Published Online First 20 October 2010
Heart 2010;96:2044. doi:10.1136/hrt.2010.208280

REFERENCES

The Authors’ reply We gratefully acknowledge receipt of the letter by David Cunningham. According to the suggestions of Dr Cunningham, we re-calculated our results2 and used the appropriate statistic (paired Student t, Wilcoxon and McNemar tests): still, quality of life (MLHFQ Score) and distance in the 6 min walk test (m) significantly improved after transcatheter aortic valve implantation (both p<0.001). In addition, levels of B-type natriuretic peptide decreased (p=0.015).

Furthermore, as the author suggests, Bonferroni correction is a suitable method to make allowance for multiple comparisons. However, our study contains only three primary study parameters (quality of life (QLHFQ Score), distance in the 6 min walk test and level of B-type natriuretic peptide), the other 13 independent comparative tests are explorative tests. Therefore, using the Bonferroni correction for three comparative tests, we considered tests to be significant not at p<0.005, but at p<0.016.

Considering all aspects, we believe that we can maintain our conclusions that transcatheter aortic valve implantation leads to a significantly clinical benefit and a reduction of neurohormonal activation in patients with severe and symptomatic aortic valve stenosis.

Michael Gotzmann, Andreas Mügge
Cardiology and Angiology, BG University-Hospital Bergmannsheil, Bochum, Germany
Correspondence to Michael Gotzmann, Bergmannsheil – Ruhr-University Bochum, Börneke-de-la-Camp-Platz 1, Bochum 44789, Germany; michael_gotzmann@web.de
Competing interests None declared.

Provenance and peer review Commissioned; not externally peer reviewed.

Published Online First 20 October 2010
Heart 2010;96:2044. doi:10.1136/hrt.2010.208298

REFERENCES

CORRECTIONS
doi:10.1136/hrt.2010.104703


Naruko T, Furukawa A, Yunoki K, et al. Increased expression and plasma levels of myeloperoxidase are closely related to the...

In table 1, the Leukocyte count (×/mm³) in SAP patients with a simple lesion was incomplete. It should have stated: 6445 (5103–7308).

**Chimenti C, Sale P, Verardo R, et al.** High prevalence of intramural coronary infection in patients with drug-resistant cardiac syndrome X: comparison with chronic stable angina and normal controls. *Heart* 2010;96:1926–31. Dr Cristina Chimenti should only have two affiliations: Department of Cardiovascular and Respiratory Sciences, La Sapienza University, Rome, Italy and the IRCCS San Raffaele La Pisana, Rome, Italy.
Increased expression and plasma levels of myeloperoxidase are closely related to the presence of angiographically-detected complex lesion morphology in unstable angina

T Naruko, A Furukawa, K Yunoki, et al.

*Heart* 2010 96: 1716-1722
doi: 10.1136/hrt.2009.187609

Updated information and services can be found at:
http://heart.bmj.com/content/96/21/1716.full.html

**References**

*These include:*

This article cites 28 articles, 15 of which can be accessed free at:
http://heart.bmj.com/content/96/21/1716.full.html#ref-list-1

Article cited in:
http://heart.bmj.com/content/96/21/1716.full.html#related-urls

**Email alerting service**

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Topic Collections**

Articles on similar topics can be found in the following collections

- Editor's choice (87 articles)
- Drugs: cardiovascular system (4851 articles)
- Stable coronary heart disease (120 articles)
- Acute coronary syndromes (1595 articles)
- Clinical diagnostic tests (2793 articles)
- Interventional cardiology (1732 articles)

**Notes**

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/